Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338920 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
A Phase 3 study, sponsored by Currax Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT03338920: Clinical Trial Phase 3 study, sponsored by Currax Pharmaceuticals.
NCT03338920 is a Phase 3 study that was terminated before completion, run by Currax Pharmaceuticals. The registered enrollment target is 159 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03338920, a Phase 3 study, was terminated before completion, sponsored by Currax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
Primary Outcome
Participants will self-report the severity of their headache.
Interventions
- DRUG Placebo
- DRUG sumatriptan nasal powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 3 |
Why NCT03338920 stopped before completion
NCT03338920 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03338920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03338920 about?
NCT03338920 is a clinical study titled "Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents". This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
What is the current status of trial NCT03338920?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2017-11-02. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT03338920?
The interventions under investigation include: Placebo (DRUG), sumatriptan nasal powder (DRUG).
Who is sponsoring clinical trial NCT03338920?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03338920's enrollment target sits among peer trials
159 1501st of 2000 higher than 499 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI